Literature DB >> 19225412

Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion.

Melissa J McGinn1, Brian J Kelley, Linnet Akinyi, Monika W Oli, Ming Cheng Liu, Ronald L Hayes, Kevin K W Wang, John T Povlishock.   

Abstract

Calpain-mediated degradation of the cytoskeletal protein alpha-II-spectrin has been implicated in the pathobiology of experimental and human traumatic brain injury (TBI). Spectrin proteolysis after diffuse/widespread TBI uncomplicated by either subtle or overt contusion and/or mass lesions, (i.e. mild to moderate TBI), has not been previously evaluated. To determine the spatiotemporal pattern and cellular localization of calpain-mediated spectrin proteolysis after diffuse/widespread TBI and the extent to which parenchymal changes in calpain-mediated spectrin proteolysis are reflected in the cerebrospinal fluid, adult rats were subjected to a moderate midline fluid percussion injury and allowed to survive for 3 hours to 7 days postinjury. Light and electron microscopic immunocytochemical and Western blot analyses were performed to identify the calpain-specific 145-kDa breakdown product of alpha-II-spectrin (SBDP145). After diffuse TBI, enhanced levels of SBDP145 immunoreactivity were observed in the neocortex, subcortical white matter, thalamus, and hippocampus, peaking between 24 and 48 hours postinjury. Immunoreactivity was localized almost exclusively to damaged axons and axonal terminal debris. Heightened levels of SBDP145 were also observed in the cerebrospinal fluid at 24 hours postinjury. These results confirm the widespread occurrence of calpain-mediated spectrin proteolysis after diffuse TBI without contusion and support the potential utility of SBDPs as biomarkers of a diffusely injured brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225412      PMCID: PMC2779123          DOI: 10.1097/NEN.0b013e3181996bfe

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  43 in total

1.  Traumatic axonal injury results in biphasic calpain activation and retrograde transport impairment in mice.

Authors:  Kathryn E Saatman; Babak Abai; Ashley Grosvenor; Christian K Vorwerk; Douglas H Smith; David F Meaney
Journal:  J Cereb Blood Flow Metab       Date:  2003-01       Impact factor: 6.200

2.  Neuroinflammatory responses after experimental diffuse traumatic brain injury.

Authors:  Brian Joseph Kelley; Jonathan Lifshitz; John Theodore Povlishock
Journal:  J Neuropathol Exp Neurol       Date:  2007-11       Impact factor: 3.685

Review 3.  Calpain in the CNS: from synaptic function to neurotoxicity.

Authors:  Jing Liu; Ming Cheng Liu; Kevin K W Wang
Journal:  Sci Signal       Date:  2008-04-08       Impact factor: 8.192

4.  Development and characterization of antibodies specific to caspase-3-produced alpha II-spectrin 120 kDa breakdown product: marker for neuronal apoptosis.

Authors:  R Nath; M Huggins; S B Glantz; J S Morrow; K McGinnis; R Nadimpalli; K K Wanga
Journal:  Neurochem Int       Date:  2000-10       Impact factor: 3.921

5.  The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury.

Authors:  N C Kupina; R Nath; E E Bernath; J Inoue; A Mitsuyoshi; P W Yuen; K K Wang; E D Hall
Journal:  J Neurotrauma       Date:  2001-11       Impact factor: 5.269

6.  Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats.

Authors:  B R Pike; J Flint; S Dutta; E Johnson; K K Wang; R L Hayes
Journal:  J Neurochem       Date:  2001-09       Impact factor: 5.372

7.  Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury.

Authors:  Nancy C Kupina; Megan R Detloff; Walter F Bobrowski; Bradley J Snyder; Edward D Hall
Journal:  Exp Neurol       Date:  2003-03       Impact factor: 5.330

Review 8.  Biomarkers of proteolytic damage following traumatic brain injury.

Authors:  Jose A Pineda; Kevin K Wang; Ronald L Hayes
Journal:  Brain Pathol       Date:  2004-04       Impact factor: 6.508

Review 9.  The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states.

Authors:  P W Vanderklish; B A Bahr
Journal:  Int J Exp Pathol       Date:  2000-10       Impact factor: 1.925

10.  Preinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury.

Authors:  A Buki; O Farkas; T Doczi; J T Povlishock
Journal:  J Neurotrauma       Date:  2003-03       Impact factor: 5.269

View more
  51 in total

1.  Comparison of rat sensory behavioral tasks to detect somatosensory morbidity after diffuse brain-injury.

Authors:  Annastazia Ellouise Learoyd; Jonathan Lifshitz
Journal:  Behav Brain Res       Date:  2011-09-16       Impact factor: 3.332

2.  Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury.

Authors:  Patrick G Sullivan; Andrea H Sebastian; Edward D Hall
Journal:  J Neurotrauma       Date:  2011-02-02       Impact factor: 5.269

3.  White matter alterations in youth with acute mild traumatic brain injury.

Authors:  Lynn Babcock; Weihong Yuan; James Leach; Tiffany Nash; Shari Wade
Journal:  J Pediatr Rehabil Med       Date:  2015

Review 4.  Axonal pathology in traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Exp Neurol       Date:  2012-01-20       Impact factor: 5.330

5.  A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model.

Authors:  Stephanie N Thompson; Kimberly M Carrico; Ayman G Mustafa; Mona Bains; Edward D Hall
Journal:  J Neurotrauma       Date:  2010-12       Impact factor: 5.269

Review 6.  How to Translate Time: The Temporal Aspects of Rodent and Human Pathobiological Processes in Traumatic Brain Injury.

Authors:  Denes V Agoston; Robert Vink; Adel Helmy; Mårten Risling; David Nelson; Mayumi Prins
Journal:  J Neurotrauma       Date:  2019-03-07       Impact factor: 5.269

7.  Does time heal all wounds? Experimental diffuse traumatic brain injury results in persisting histopathology in the thalamus.

Authors:  Theresa Currier Thomas; Sarah B Ogle; Benjamin M Rumney; Hazel G May; P David Adelson; Jonathan Lifshitz
Journal:  Behav Brain Res       Date:  2016-12-29       Impact factor: 3.332

8.  Moderately elevated intracranial pressure after diffuse traumatic brain injury is associated with exacerbated neuronal pathology and behavioral morbidity in the rat.

Authors:  Audrey D Lafrenaye; Thomas E Krahe; John T Povlishock
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-16       Impact factor: 6.200

9.  Preclinical Western Blot in the Era of Digital Transformation and Reproducible Research, an Eastern Perspective.

Authors:  Saman Sargolzaei; Ajeet Kaushik; Seyed Soltani; M Hadi Amini; Mohammad Reza Khalghani; Navid Khoshavi; Arman Sargolzaei
Journal:  Interdiscip Sci       Date:  2021-06-02       Impact factor: 2.233

10.  Therapy development for diffuse axonal injury.

Authors:  Douglas H Smith; Ramona Hicks; John T Povlishock
Journal:  J Neurotrauma       Date:  2013-02-14       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.